NCT02156895View on ClinicalTrials.gov

Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

CompletedOBSERVATIONAL
Enrollment

111

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

April 21, 2021

Study Completion Date

August 6, 2021

Conditions
Advanced Renal Cell Carcinoma
Interventions
DRUG

Axitinib

based on Axitinib approval

Trial Locations (1)

04631

Pfizer Tower, Seoul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02156895 - Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | Biotech Hunter | Biotech Hunter